Recent Updates — NCEL

NewcelX Ltd. filed its interim financial statements for the six months ended June 30, 2026, reporting a net loss of $2.9 million and cash on hand of $710 thousand. The company raised $1.35 million in April 2026 through a PIPE offering at $2.75 per share, which triggered down-round provisions reducing the conversion prices of legacy preferred shares and warrants to that level. Subsequent to quarter-end, NewcelX closed another private placement on July 30, 2026, raising $1.4 million at $4.033 per share. The filing also discloses a successful Pre-IND meeting with the FDA for its lead program NCEL-101 and notes substantial doubt regarding the company's ability to continue as a going concern due to recurring losses and limited cash reserves. NewcelX Ltd. is a clinical-stage biopharmaceutical company developing stem cell-based therapies for Type 1 Diabetes and neurodegenerative diseases.

NewcelX Ltd. announced a successful FDA Pre-IND meeting regarding its NCEL-101 candidate, establishing a clear pathway toward initiating clinical trials for the treatment of Type 1 diabetes. The company intends to use the feedback from this meeting to advance its regulatory strategy. NewcelX Ltd. is a biotechnology company focused on developing therapeutic treatments.

NewcelX Ltd. held its Annual General Shareholders’ Meeting on June 30, 2026, where shareholders approved all presented proposals. The specific details of these proposals were previously disclosed in the Notice and Invitation filed on June 5, 2026. NewcelX Ltd. is a Swiss-based company involved in the technology sector.

NewcelX Ltd. published a peer-reviewed study demonstrating the therapeutic potential of its stem cell technology platform. The company is a biotechnology company focused on developing stem cell-based therapies.